Omega-3 Phospholipids (Eye).

Lutein is fat soluble and needs a lipid phase to leave the food matrix and enter micelles. Phospholipids provide that emulsified phase, which is why lutein is routinely formulated with them.

Zeaxanthin shares lutein's absorption route and depends on the same micellar lipid phase. A phospholipid vehicle keeps it dispersed rather than crystalline.

Retinal membranes are the most DHA-dense phospholipid tissue in the body, with DHA esterified directly into the bilayer. Phospholipid-bound DHA delivers the fatty acid in the form the membrane already uses.

Astaxanthin sits across the phospholipid bilayer with its polar ends at both membrane surfaces, quenching radicals in the lipid interior. It also depends on a lipid vehicle for absorption, which phospholipids supply.

Dietary EPA and DHA are incorporated into membrane phospholipids after absorption, so the two are the same pool at different stages. Phospholipids also emulsify the oil, reducing reliance on bile flow.

Krill oil is itself a phospholipid-bound omega-3 source, so stacking it with added phospholipids raises the same lipid class twice. The combination is coherent but the doses add rather than complement.

Bilberry anthocyanins are polar and poorly retained, and complexing them with phospholipids is an established way to raise their systemic exposure. The pairing is a delivery relationship rather than a shared mechanism.

The highly unsaturated phospholipids of ocular tissue are prime targets for lipid peroxidation, and tocopherol terminates those chain reactions from inside the same bilayer. Tocopherol also protects the phospholipid raw material in the capsule.

Phosphatidylcholine is the main species inside an eye-targeted phospholipid blend, so the two overlap directly. Their intakes stack rather than complement.

Phosphatidylserine is the other major acidic phospholipid of neural membranes and is enriched in the same DHA-heavy inner leaflet as phosphatidylethanolamine and phosphatidylcholine. Retinal photoreceptors are neural tissue with the highest membrane turnover in the body. The two supply different head groups of the same membrane class rather than competing.

Taurine is the most abundant free amino acid in the retina and stabilises photoreceptor membranes and osmotic balance there. Depletion in animal models produces photoreceptor loss. Its role is membrane-protective rather than structural, which pairs with the structural role of DHA-bearing phospholipids.

Zinc concentrates in the retinal pigment epithelium and choroid, where it is the cofactor for retinol dehydrogenase in the visual cycle and for retinal antioxidant enzymes. Phospholipid DHA supplies the membrane that cycle runs in. The pairing appears in eye formulas because the two cover substrate and enzymatic handling.

Sustained zinc intake induces intestinal metallothionein, which binds copper and reduces its absorption. Eye formulas that carry meaningful zinc conventionally include copper to hold the ratio. This is a formulation correction, not an additive effect on the eye.

11-cis-retinal is the chromophore that sits inside opsin in the photoreceptor disc membrane, and it comes from dietary vitamin A. The disc membrane itself is the DHA-rich phospholipid bilayer. Without retinal there is no photopigment; without the phospholipid environment the pigment does not cycle at normal speed.

Beta-carotene is cleaved centrally by beta-carotene 15,15-dioxygenase to two molecules of retinal, the regulated route by which plant sources meet vitamin A need. Conversion falls as vitamin A status rises, so it does not stack in a linear way. In an eye formula it is an alternative retinoid source alongside phospholipid DHA, not a duplicate of it.

Dietary phospholipids are hydrolysed at the sn-2 position by pancreatic phospholipase A2 to lysophospholipid and free fatty acid before uptake, and neighbouring triglyceride is handled by pancreatic lipase. Where pancreatic output is reduced, absorption of any lipid-carried nutrient falls with it. Enzyme support is relevant to delivery, not to the eye directly.

Glutathione peroxidase 4 is the enzyme that reduces phospholipid hydroperoxides while they are still inside the membrane, the only peroxidase that can act on an esterified lipid. Highly unsaturated DHA-containing phospholipids are the most peroxidation-prone lipids in the body. Supplying long-chain polyunsaturated phospholipid without regard to the reductive side leaves the more oxidisable substrate unprotected.

Dihydrolipoic acid regenerates ascorbate and, indirectly, alpha-tocopherol, feeding the network that protects membrane lipids from chain oxidation. It is amphiphilic, so it reaches both the aqueous and lipid phases. Its relevance to a phospholipid product is protection of the delivered fatty acid rather than an ocular action of its own.

Ascorbate at the membrane surface reduces the tocopheroxyl radical back to alpha-tocopherol, which is what allows a small amount of vitamin E to interrupt many peroxidation chains. Aqueous humour holds ascorbate at a concentration well above plasma. The pairing matters most where the delivered lipid is highly unsaturated.

Tocotrienols have an unsaturated side chain that distributes differently within the bilayer than tocopherol and shows greater mobility in membrane models. That physical difference is described in laboratory work rather than in ocular outcome trials. Where a formula already carries alpha-tocopherol, adding tocotrienols is a distribution argument, not an extra dose of the same thing.

Lecithin is a mixed phospholipid concentrate dominated by phosphatidylcholine, the same class as the marine phospholipids used here but with shorter, less unsaturated fatty acids. A small report in adults with dry eye symptoms measured meibomian gland function after sunflower lecithin supplementation. It functions in a formula as both a phospholipid source and an emulsifier for the marine fraction.

EPA and DHA compete for the same elongation and desaturation enzymes and for incorporation into membrane phospholipids, and EPA is the substrate for the resolvin E series while DHA feeds the D series. Ocular tissue concentrates DHA specifically. A phospholipid product weighted to DHA and a separate EPA source are addressing different ends of the same family.

Curcumin is poorly water soluble and its absorption rises substantially when it is carried in a phospholipid complex, which is why phytosome presentations exist. A marine phospholipid in the same capsule supplies exactly that kind of amphiphilic carrier. The interaction is about delivery of the curcumin, and it has not been measured in this specific combination.

Like curcumin, resveratrol is lipophilic and shows higher measured exposure when formulated with phospholipid. Any co-formulated phospholipid can act as that vehicle. This is a formulation-level observation and no combination study addresses the two together for an ocular endpoint.